Archives202520242023202220212020201920182017201620152014201320122011Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor on recent news which confirms that Lupuzor will move into a Phase 2/3 adaptive study in H2 2023 – February 2023 14th February 2023 - 2:41 pmShare this article Share on Facebook Share on Twitter
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor on recent news which confirms that Lupuzor will move into a Phase 2/3 adaptive study in H2 2023 – February 2023 14th February 2023 - 2:41 pm